Search results for "MAb"

Metālisko elementu satura variācijas augsnē un dārzeņos

2022

Metālisko elementu satura variācijas augsnē un dārzeņos. Lazdiņa L., darba vadītājs lekt., Mg.chem. Balcerbule Z. Bakalaura darbs, 45 lappuses, 11 attēli, 22 tabulas, 51 literatūras avots, 6 pielikumi. Latviešu valodā. Bakalaura darba ietvaros tika ievākti, sagatavoti un analizēti augsnes paraugi no 2 dažādiem laukiem ar līdzīgu granulometrisko sastāvu. Analīzei ievāca arī šajos laukos audzētus burkānus (daucus carota), bietes (beta vulgaris) un kartupeļus (solanum tuberosum). Augsnes un dārzeņu paraugos ar liesmas atomabsorbciometru noteica vara, cinka, dzelzs un mangāna saturu, dārzeņu paraugos papildus noteica arī mitruma saturu. Augsnes un dārzeņu paraugos ar induktīvi saistītās plazmas…

Microstructural Characterization of Thermo-Mechanical Treated TRIP Steels

2007

The increasing demand for the reduction of automobiles CO2 emissions for environmental preservation leads the automotive industries towards the mechanical components weight reduction. Sheet steels with multiphase microstructures exhibit favourable combinations of strength and ductility. The so called TRIP steels have a metastable microstructure that consists of a continuous ferrite matrix containing a dispersion of hard second phases martensite and bainite. These steels also contain retained austenite, at room temperature, that represents the source of the TRansformation Induced Plasticity effect. When the material is subjected to deformation step, the retained austenite transforms itself i…

Pathogenesis of primary Sjögren's syndrome beyond B lymphocytes

2020

Primary Sjögren's syndrome (pSS) is a chronic autoimmune disorder affecting exocrine glands of the body, prevalently lacrimal and salivary glands. The pSS pathogenesis has been thought to be B-cell-centric and several clinical trials have been carried out in order to clarify the therapeutic role of B-cell depletion in patients with pSS. Unfortunately, however, B-cell depletion with rituximab has failed in demonstrating any significant results in pSS patients. Besides the contribution of B cells in the pathogenesis of pSS, effector Tfh, Th17 and Th22 cells, follicular dendritic cells (DCs), innate cells (ICs) and several cytokines, chemokines and miRNA have been proved to participate to the …

RELATIONSHIP BETWEEN BRAIN ATROPHY AND NATALIZUMAB THERAPY IN THE TREATMENT OF MULTIPLE SCLEROSIS

2015

Experimental Evaluation of the Performance of a Three-Phase Five-Level Cascaded H-Bridge Inverter by Means FPGA-Based Control Board for Grid Connecte…

2018

Over the last decades, plants devoted to the generation of green energy significantly increased their number, together with the demand of same electrical energy, also stored in battery systems. This fact produced the growth of energy conversion systems with advanced performances with respect to the traditional ones. In this circumstance, multilevel converters play a significant role for their great advantages in performances, flexibility, fault-tolerability, employment of renewable energy sources and storage systems and finally yet importantly reduced filter requirements. In this context, this paper faces the performance of a cascaded H-bridge 5 level inverter in terms of harmonic distortio…

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.

2018

Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable disease control in patients with splenic marginal zone lymphoma (SMZL). However, systemic chemotherapy is ultimately required in many cases. The BRISMA (Bendamustine-rituximab as first-line treatment of splenic marginal zone lymphoma)/IELSG (International Extranodal Lymphoma Study Group)36 trial is an open-label, single arm phase II study designed by the IELSG in cooperation with the Fondazione Italiana Linfomi and the lymphoma Study Association according to Simon's two-stage method. The primary endpoint was complete response rate. Fifty-six patients with SMZL diagnosis confirmed on central revis…

High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multice…

2006

Abstract Purpose: Bendamustine is a new anti-lymphoma agent with promising activity. Based on a preceeding phase I study the current trial explored Bendamustine in combination with Mitoxantrone and Rituximab (BMR) in patients with relapsed or refractory indolent lymphomas. Patients and Methods: Patients with relapsed or refractory symptomatic stage III/IV indolent lymphomas with or without prior treatment with Rituximab were eligible. Therapy consisted of Bendamustine 90 mg/m2 days 1+2, Mitoxantrone 10 mg/m2 day 1, Rituximab 375 mg/m2 day 8. Treatment was repeated on day 29 for a total of 4 cycles. Results: Between 04/03 and 07/04 62 patients were recruited from 24 participating institution…

ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R)…

2021

Context Tafasitamab+LEN, a chemotherapy-free, novel treatment for R/R DLBCL, demonstrated efficacy in ASCT-ineligible patients in the single-arm Phase II L-MIND study (NCT02399085). Objective To compare outcomes in patients treated with tafasitamab+LEN in the L-MIND study with matched patient populations treated with commonly administered NCCN-/ESMO-recommended therapies for non-transplant-eligible patients with R/R DLBCL in routine clinical practice. Design RE-MIND2 (NCT04150328) is an observational, retrospective cohort study. The L-MIND tafasitamab+LEN cohort was matched with RE-MIND2 patients using estimated propensity score-based 1:1 nearest neighbor matching balanced for nine patient …

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

2021

The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and brid…

Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/I…

2016

Abstract Background: mTOR inhibition has been shown to be effective in various subtypes of malignant lymphomas (Smith et al, JCO 2010). Furthermore, in relapsed MCL a phase III trial demonstrated superiority of Temsirolimus to chemotherapy. Although novel treatment options as Ibrutinib have changed the treatment landscape for MCL, no curative potential could be shown for this approach and novel concepts continue to be needed. Several trials provided promising results when Temsirolimus is combined with agents like Rituximab (Ansell et al, Lancet Oncology 2011) or chemoimmunotherapy, as shown in part I (phase I) of the reported trial (Hess, Leukemia, 2015). We now report the final analysis of…